NovoCure, a commercial-stage oncology company developing monotherapy treatments for glioblastoma brain cancer, filed on Monday with the SEC to raise up to $300 million in an initial public offering.
The St Helier, Jersey-based company, which was founded in 2000 and booked $20 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol NVCR. J.P. Morgan, Deutsche Bank and Evercore Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
